Feasibility of FMISO in Brain Tumors
ConditionMalignant Brain Neoplasm
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorOHSU Knight Cancer Institute
About this trial
This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.
Eligibility criteria
Qualifiers
Adult patients (greater than 18 years of age) with a known or suspected intracranial tumor.
Able to provide informed written consent and/or acceptable surrogate capable of providing consent on the patient's behalf.
Legally authorized representative (LAR)-signed informed consent and assent obtained for those subjects identified as decisionally impaired
Intracranial lesion known or suspected to be neoplastic greater than 10 mL as assessed by T2/fluid attenuated inversion recovery (FLAIR) MR imaging.
Disqualifiers
Pregnant or breast feeding.
Contraindication to PET, MRI, FMISO, or intravenous gadolinium based contrast agents.
Claustrophobia.
Weight greater than modality maximum capacity.
Trial design
Treatments tested in this trial
- ¹⁸F-Fluoromisonidazole
- Computed Tomography
- Magnetic Resonance Imaging
- Positron Emission Tomography
- Oxygen Therapy
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
OHSU Knight Cancer Institute
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Oregon Health and Science University
Collaborator
Weill Cornell University
Collaborator
Source ClinicalTrials.gov